Results 101 to 110 of about 15,068 (213)

Next‐Generation Strategies for Neural Repair and Regeneration: Neural Organoid Transplantation in the CNS

Cell Proliferation, Volume 59, Issue 6, June 2026.
Neurological disorders are hard to treat. Stem cell‐derived neural organoids enable research, and their transplantation aids CNS therapy, with this article reviewing relevant advances, challenges and prospects. ABSTRACT Neurological disorders are often devastating and notoriously difficult to repair, creating an urgent need for novel research models ...
Yutong Wang, Jinrui Li, Xingjia Mao, Wanyu Wang, Yansong Li, Xuefei Hu, Jinjie Zhong, Fengdong Zhao, Linlin Wang   +8 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Neuropilin-1 inhibition suppresses nerve growth factor signaling and nociception in pain models

The Journal of Clinical Investigation
Nerve growth factor (NGF) monoclonal antibodies inhibit chronic pain, yet failed to gain approval due to worsened joint damage in osteoarthritis patients.
Chloe J. Peach, Raquel Tonello, Elisa Damo, Kimberly Gomez, Aida Calderon-Rivera, Renato Bruni, Harsh Bansia, Laura Maile, Ana-Maria Manu, Hyunggu Hahn, Alex R.B. Thomsen, Brian L. Schmidt, Steve Davidson, Amedee des Georges, Rajesh Khanna, Nigel W. Bunnett   +15 more
doaj   +1 more source

From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Systemic therapies for advanced hepatocellular carcinoma (HCC) have expanded considerably with the advent of tyrosine kinase inhibitors, immune checkpoint inhibitors and immunotherapy–anti‐angiogenic combinations. However, despite this therapeutic diversification, first‐line treatment selection remains largely empirical, as few biomarkers are ...
Marie Decraecker, Jean‐Frédéric Blanc, Samuel Amintas, Grégoire Manaud   +3 more
wiley   +1 more source

Sema4A-Nrp1 versus Sema4A-plexinB2 in the acutely damaged kidney

Kidney International, 2022
I read with great interest the article by Xu et al., recently published in Kidney International. This study reported that Semaphorin 4A (Sema4A) systemic delivery could help recruit neuropilin-1 (Nrp1)–positive regulatory T cells to the kidney and alleviate ischemia-reperfusion injury (IRI). These encouraging results need to be reconciled with previous
openaire   +2 more sources

Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease.

, 2020
Psoriasis is a common chronic skin disorder characterized by keratinocyte hyperproliferation with altered differentiation accompanied by inflammation and increased angiogenesis.
Blanpain, Cédric, Brisebarre, Audrey, Song, Yura, Del Marmol, Véronique, Sibilia, Maria, Benhadou, Farida, Glitzner, Elisabeth, Dubois, Christine, Swedlund, Benjamin, Rozzi, Milena, Paulissen, Catherine   +10 more
core   +1 more source

Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues

Cancer Management and Research, 2018
Mahnaz Seifi-Alan,1 Roshanak Shams,1 Mojgan Bandehpour,2 Reza Mirfakhraie,1 Soudeh Ghafouri-Fard1 1Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Biotechnology, School of Advanced Technologies
Seifi-Alan M, Shams R, Bandehpour M, Mirfakhraie R, Ghafouri-Fard S   +4 more
doaj  

NRP1 como potencial alvo molecular para meduloblastoma

BioSCIENCE
Introdução: Meduloblastoma é tumor maligno, altamente agressivo e de rápido crescimento que surge no cerebelo ou no assoalho do quarto ventrículo e tronco cerebral, especialmente em crianças. Mesmo com avanços na terapia, a morbimortalidade permanece grande desafio. Por isso, novos tratamentos são necessários para reduzir esses desfechos.
Moisés Augusto De Araujo, Paulo Afonso Nunes Nassif, Livia Fratini, Rafael Roesler, Samuel Rabello, Alexsandro Batista da Costa Carmo, Gustavo Rassier Isolan   +6 more
openaire   +1 more source

Characterization of Konjac Ceramide (kCer) Binding to Sema3A Receptor Nrp1

Journal of Oleo Science, 2018
Konjac ceramide (kCer) can be prepared by a chemoenzymatic method as previously published (Usuki, S.; Tamura, N.; Sakai, S.; Tamura, T.; Mukai, K.; Igarashi, Y. Biochem. Biophys. Rep. 5, 160-167 (2016)). Thus prepared kCer showed an activation effect on Sema3A signaling pathway to induce phosphorylation of CRMP2 and microtubule depolymerizaion ...
Usuki, Seigo, Tamura, Noriko, Tamura, Tomohiro, Mukai, Katsuyuki, Igarashi, Yasuyuki   +4 more
openaire   +3 more sources

Nrp2 and Nrp1^Chimera preferentially sequester Sema3F.

, 2012
The ability of Nrp1, Nrp2, and Nrp1Chimera to selectively sequester C-furSema was determined through combined incubation of Nrp, C-furSema3F, and AP-VEGF-A in Nrp1 adsorbed affinity plates.
Hou-Fu Guo (122621), Ping Xu (122619), Craig W. Vander Kooi (122623), Matthew W. Parker (122616)   +3 more
core   +1 more source